Cancer research demands antibodies that perform in living tumor systems, not just bind. Bio X Cell functional antibodies enable blocking, depletion, activation, and neutralization across murine tumor models and human-relevant systems, with ultra-low endotoxin (≤0.5 EU/mg), carrier-free formulations that protect tumor microenvironment biology by eliminating cytokine artifacts.
The same clones move seamlessly across model systems and scales with no switching and no reformulation, keeping checkpoint, cytokine, and tumor microenvironment biology consistent from in vivo studies through downstream translational workflows.
Backed by nearly 30,000 peer-reviewed citations, Bio X Cell sets the standard for reproducible, in vivo-ready functional antibodies in cancer research.
Scientific Posters for Antibody-Based Cancer Research
Designed for researchers working with antibodies in cancer research, these posters highlight critical pathways and mechanisms, from immune checkpoints to cytokine networks, to support informed study design and biological interpretation across experimental systems.
Cancer Model Systems
Scientists engaged in cancer drug development utilize a range of model systems, including various in vivo, in vitro, and emerging approaches. Antibodies play an important role in this research and discovery process, with researchers facing questions about how to match model systems to applications and models to antibodies.
Insights on Functional Antibodies for Cancer Research
Explore expert perspectives on cancer immunology, tumor microenvironment biology, and antibody-based research. Our articles examine how ultra-pure, low-endotoxin functional antibodies minimize experimental artifacts and support reproducible, biologically meaningful outcomes across cancer research workflows.
How the Tumor Microenvironment Drives Cancer Progression
The tumor microenvironment shapes cancer progression, immune evasion, and therapeutic response. This article explores how immune cells, cytokines, and checkpoint pathways interact within the TME, and how functional antibodies enable precise interrogation of these complex dynamics in cancer research.
Comparing PD-1 and PD-L1 Mouse Monoclonal Antibodies
Checkpoint blockade studies depend on selecting the right antibody clone for your model. This article compares commonly used murine PD-1 and PD-L1 antibodies, highlighting differences in binding affinity, blocking activity, and functional outcomes to help guide more informed experimental design in immuno-oncology research.
Emerging Therapeutic Strategies in Cancer Research
Cancer research is entering a new era of precision and complexity, driven by advances in immunotherapy and translational science. This article highlights key insights from leading experts on how emerging therapeutic strategies are reshaping cancer research from preclinical discovery to clinical impact.
Expert Videos on Functional Antibodies for Cancer Research
Discover expert-led webinars exploring cancer immunology, tumor microenvironment biology, and antibody-based research. These on-demand videos feature scientific discussions on how ultra-pure, low-endotoxin functional antibodies minimize experimental artifacts and support reproducible, biologically meaningful outcomes across cancer research workflows.
Checkpoint Blockade, Escape and Beyond in Cancer Immune Modulation
PD-1 signaling is a central regulator of T-cell function and a cornerstone of cancer immunotherapy. In this webinar, Dr. Gordon Freeman explores how PD-1 blockade antibodies are used to dissect checkpoint biology, study T-cell exhaustion, and model immune responses in preclinical cancer research.
Scientific Posters for Antibody-Based Cancer Research
Designed for researchers working with antibodies in cancer research, these posters highlight critical pathways and mechanisms, from immune checkpoints to cytokine networks, to support informed study design and biological interpretation across experimental systems.
Cancer Model Systems
Scientists engaged in cancer drug development utilize a range of model systems, including various in vivo, in vitro, and emerging approaches. Antibodies play an important role in this research and discovery process, with researchers facing questions about how to match model systems to applications and models to antibodies.
Insights on Functional Antibodies for Cancer Research
Explore expert perspectives on cancer immunology, tumor microenvironment biology, and antibody-based research. Our articles examine how ultra-pure, low-endotoxin functional antibodies minimize experimental artifacts and support reproducible, biologically meaningful outcomes across cancer research workflows.
How the Tumor Microenvironment Drives Cancer Progression
The tumor microenvironment shapes cancer progression, immune evasion, and therapeutic response. This article explores how immune cells, cytokines, and checkpoint pathways interact within the TME, and how functional antibodies enable precise interrogation of these complex dynamics in cancer research.
Comparing PD-1 and PD-L1 Mouse Monoclonal Antibodies
Checkpoint blockade studies depend on selecting the right antibody clone for your model. This article compares commonly used murine PD-1 and PD-L1 antibodies, highlighting differences in binding affinity, blocking activity, and functional outcomes to help guide more informed experimental design in immuno-oncology research.
Emerging Therapeutic Strategies in Cancer Research
Cancer research is entering a new era of precision and complexity, driven by advances in immunotherapy and translational science. This article highlights key insights from leading experts on how emerging therapeutic strategies are reshaping cancer research from preclinical discovery to clinical impact.
Expert Videos on Functional Antibodies for Cancer Research
Discover expert-led webinars exploring cancer immunology, tumor microenvironment biology, and antibody-based research. These on-demand videos feature scientific discussions on how ultra-pure, low-endotoxin functional antibodies minimize experimental artifacts and support reproducible, biologically meaningful outcomes across cancer research workflows.
Checkpoint Blockade, Escape and Beyond in Cancer Immune Modulation
PD-1 signaling is a central regulator of T-cell function and a cornerstone of cancer immunotherapy. In this webinar, Dr. Gordon Freeman explores how PD-1 blockade antibodies are used to dissect checkpoint biology, study T-cell exhaustion, and model immune responses in preclinical cancer research.
